BDTX
Black Diamond Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$143.22M
P/E Ratio
6.41
EPS
$0.39
Beta
3.39
52W High
$4.94
52W Low
$1.20
50-Day MA
$2.31
200-Day MA
$2.93
Dividend Yield
—
Profit Margin
32.00%
Forward P/E
8.33
PEG Ratio
—
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $70.00M |
| Gross Profit (TTM) | $70.00M |
| EBITDA | $20.20M |
| Operating Margin | 28.40% |
| Return on Equity | 22.90% |
| Return on Assets | 9.35% |
| Revenue/Share (TTM) | $1.23 |
| Book Value | $1.96 |
| Price-to-Book | 1.22 |
| Price-to-Sales (TTM) | 2.05 |
| EV/Revenue | 0.386 |
| EV/EBITDA | 1.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $57.29M |
| Float | $46.25M |
| % Insiders | 0.62% |
| % Institutions | 77.45% |
Analyst Ratings
Consensus ($9.71 target)
2
Strong Buy6
Buy1
HoldData last updated: 4/7/2026